A randomised, double-blind, active controlled study of Brintellix® (vortioxetine) versus agomelatine in adults with Major Depressive Disorder with inadequate response to antidepressant treatment
In MDD patients with an inadequate response to SSRI/SNRI treatment, switching to Brintellix® (vortioxetine) resulted in a significant and superior improvement versus agomelatine on the primary efficacy endpoint (MADRS) starting from week 4 to week 12.
The Brintellix® (vortioxetine) remission rate after 8 and 12 weeks of treatment was significantly higher than for agomelatine. There is also significant advantage of vortioxetine compared to agomelatine seen in the overall functioning and HRQoL assessments confirms the clinical relevance of the finding.
The Brintellix® (vortioxetine) remission rate after 8 and 12 weeks of treatment was significantly higher than for agomelatine. There is also significant advantage of vortioxetine compared to agomelatine seen in the overall functioning and HRQoL assessments confirms the clinical relevance of the finding.
In a recent analysis published in 2023, Brintellix® (vortioxetine) was reported to be superior to agomelatine in improving MDD symptoms, overall functioning and HRQoL measured by SDS (Sheehan Disability Scale) & DFFS (Depression and Family Functioning Scale_), in patients with MDD and high levels of anxiety.
In a recent analysis published in 2023, Brintellix® (vortioxetine) was reported to be superior to agomelatine in improving MDD symptoms, overall functioning and HRQoL measured by SDS (Sheehan Disability Scale) & DFFS (Depression and Family Functioning Scale_), in patients with MDD and high levels of anxiety.
Abbreviations:
MADRS: Montgomery-Åsberg Depression Rating Scale; MDD - Major Depressive Disorder; HRQoL: Health-related Quality of Life; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
Abbreviations:
MADRS: Montgomery-Åsberg Depression Rating Scale; MDD - Major Depressive Disorder; HRQoL: Health-related Quality of Life; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.